Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + ruxolitinib versus placebo + ruxolitinib in treatment-naive myelofibrosis
NL-OMON58691Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Selinexor + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoints: Spleen volume reduction at Week 24 and Absolute mean change in total symptom score at Week 24. Started Jun 2024; status: active, not recruiting.
02
Drugs
selinexorruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON58691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58691.